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the extracellular space to fight bacteria. The α-defensin human neutrophil peptides 1 to 3 (HNPs 1-3) are abundant in these granula; these peptides are bactericidal and modulate the production of the chemokine interleukin-8 (IL-8). 14 Third, in a process called NETosis, neutrophils fight bacteria by releasing their chromatin into the extracellular space, where the chromatin forms neutrophil extracellular traps (NETs). 15 Transient disturbances in phagocytosis and the associated mechanisms for bacterial killing were previously detected in systemic infection and in traumatic brain injury. 16, 17 Also, reduced phagocytosis has been described in subjects >65 years. 18 Little is known about phagocyte function in stroke, but there are hints that it may also be disturbed. One study reported impaired neutrophil burst in a small cohort of patients with intracranial hemorrhage who required neurosurgical intervention, 19 whereas an earlier report suggested the occurrence of alterations in neutrophil function in patients with stroke, as indicated by measurement of the granulocyte antisedimentation rate. 20 To shed light on this issue and to increase our understanding of SIIAs, we investigated the key steps of bacterial defense by phagocytes in patients with stroke.
Materials and Methods

Patients and Controls
Patients ≥18 years old having acute media infarct were eligible for this study within 12 hours of disease onset if their National Institute of Health Stroke Scale Score (NIHSS) was ≥6 and no signs of infection were detected, C-reactive protein was ≤50 mg/L, and procalcitonin was ≤0.5 ng/mL. Patients were recruited between June 2011 and February 2013 at the Department of Neurology of the University Medicine, Greifswald, Germany. Patients were treated with standard medical care in a dedicated stroke unit and did not receive immune-suppressive drugs. Recombinant tissue plasminogen activator and thrombectomy were administered as clinically indicated.
Age-matched control individuals were either healthy or were recruited from the ophthalmology clinics from patients scheduled to receive cataract surgery. (For patient and control characteristics, see the Table. )
Definition of SAI
To define SAI, we used the same stringent criteria applied in our previous studies that identify patients with definite systemic infection and those without any sign of infection. 5 SAI was diagnosed if (1) clinical signs of infection were present; (2) serum concentrations of C-reactive protein were >50 mg/L; and (3) procalcitonin serum concentrations were >0.5 ng/mL. Absence of SAI was assumed if none of the criteria was met. Patients who matched 1 or 2 criteria were not assigned to either cohort. The study protocol was approved by the ethics committee of the Medical Faculty, University of Greifswald (No. III UV 30/01). All patients provided written informed consent directly or through a surrogate where appropriate. Details on patients who are SAI+ and SAI− are given in the Table I in the online-only Data Supplement.
Cerebral Computed Tomography
Routine cerebral computed tomographic (cCT) images (sequential cCT native, 4.5 mm layer thickness supra-and infratentorial; mAs=50; kV=120) were acquired on a 16-row multislice CT scanner (Somatom 16, Siemens Medical Systems, Erlangen, Germany). Images were analyzed using OSIRIX 5.6. Regions of interest were defined manually, and the lesion volume was calculated semiautomatically.
Blood Sampling
Blood was obtained immediately on admission and between 6:00 AM and 8:00 AM on days 1, 3, 5, and 7. Investigators were not blinded for control and samples of patients with stroke but were unaware of SAI status.
Migration
Cell migration was assayed using the MIGRATEST Kit (Glycotope Biotechnology GmbH, Heidelberg, Germany) according to the manufacturer instructions. Details are given in the online-only Data Supplement.
Phagocytosis
The Phagotest Kit (Biotechnology GmbH, Heidelberg, Germany) was used according to the manufacturer instructions to quantify phagocytosis. In brief, heparinized whole blood was incubated with FITC (fluoresceinisothiocyanat) labeled Escherichia coli (E coli) for 10 minutes at 37°C (activated sample). A control sample was kept on ice to determine the background. Thereafter, all cells were transferred on ice; samples were quenched to eliminate the signal of adherent nonphagocytosed bacteria. Erythrocytes were lysed, and cells were washed. Debris and dead cells were excluded by 4′,6-diamidino-2-phenylindole (DAPI) staining. Phagocytes that had internalized E coli were quantified by determining the FITC fluorescence signal by flow cytometry on a BD LSR II. Anti-CD14 antibodies (hCD14 antigen presenting cell; clone M5E2; BD Biosciences) labeling was used to clearly distinguish monocytes from neutro- 
Oxidative Burst
Heparinized whole blood was incubated with the fluorogenic substrate dihydrorhodamine 123 and either remained unstimulated or was incubated with unlabeled opsonized E coli, phorbol 12-myristate 13-acetate (PMA), or N-formyl-methionyl-leucyl-phenylalanine (fMLP) as stimulants for 10 minutes at 37°C. Conversion into rhodamine 123 served as a marker for the quantification of reactive oxidants and allowed determination of the percentage of phagocytes that underwent oxidative burst. The enzymatic activity per cell was quantified by MFI and is termed efficacy. Oxidative burst was measured by flow cytometry on a BD Canto II (BD Biosciences) using the Phagoburst Kit (Glycotope Biotechnology GmbH) according to the manufacturer instructions. Twenty-thousand leukocytes were acquired. Anti-CD14 antibodies (CD14 V450, clone MФP9; BD Biosciences) were added to clearly distinguish monocyte burst from neutrophil burst. The flow cytometry results were evaluated with FlowJo Software 7.6.5 (Tree Star Inc, Ashland, OR).
Hormonal effects on respiratory burst in vitro were assessed by preincubating whole blood for 24 hours at 37°C, 5% CO 2 in the presence of 1×10 −7 mol/L epinephrine or norepinephrine (epinephrine, norepinephrine from Sigma, Deisenhofen, Germany), or 2.5×10 −6 mol/L dexamethasone (MerckPharmaGmbH, Darmstadt), followed by a burst test. Additionally, we tested 5.5×10 −6 mol/L acetylcholine (Sigma, Deisenhofen, Germany) to quantify the influence of this autonomic nervous system neurotransmitter on burst activity. Diluents without hormones or acetylcholine served as controls.
Serum Hormones
Metanephrine is the inactive methylation product of epinephrine with longer plasma half-life. 21 In this study, we determined metanephrine to assess the magnitude of the adrenergic response after stroke in patients with and without SAI. Metanephrine levels were determined in serum samples after storage at −80°C by competitive ELISA according to the manufacturer recommendations (MetCombi plasma ELISA; IBL, Hamburg, Germany).
HNPs 1 to 3
The production of HNPs 1 to 3 by neutrophils was determined by standard sandwich enzyme-linked immunosorbent assay (ELISA) according to the manufacturer instructions (Hycult Biotech, Uden, The Netherlands) from serum samples stored at −80°C.
NETosis Assay
Neutrophils were separated from heparinized whole blood by standard Histopaque/Percoll gradient centrifugation. Neutrophils were resuspended in Hanks' Balanced Salt Solution (HBSS) and diluted to 5×10 4 cells/mL. The cell suspension was plated in 24-well plates (1 mL/well) and allowed to rest for 30 minutes at 37°C, 5% CO 2 . Thereafter, neutrophils remained unstimulated or were stimulated with either fMLP (0.9 nmol/L) or PMA (1.5 nmol/L) for 2 hours at 37°C, 5% CO 2 . DNA was stained with SYTOX Green Nucleic Acid Stain (Invitrogen, Eugene), and fluorescent and phase contrast images were taken of 10 spots per well using a LEICA DBMI-4000b microscope. Total and NEToting cells were counted, and the fluorescent area covered by each cell was measured using Fiji Software Version 1.46 to calculate percentage and efficacy of NETosis. The NET threshold was set at ≥300 μm 2 .
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Statistical Analyses
All data sets were tested for adherence to the Gaussian distribution with the Kolmogorov−Smirnov test. Multiple comparisons of Gaussian-distributed data were performed using analysis of variance and the Bonferroni correction for multiple comparisons as a post-test. Because some of the data in each experiment failed the normality test, we used nonparametric testing throughout. The Kruskal−Wallis test with Dunn's multiple comparison test as a post-test or the Mann−Whitney test were used as appropriate. Post-tests were only performed when initial testing revealed significant differences between groups. Correlations were determined by Spearman analysis. GraphPad-PRISM 5.0 (GraphPad Software Inc, San Diego, CA) was used for all analyses. A P value <0.05 was regarded as significant.
Results
Cellular Alterations in the Peripheral Blood of Patients With Stroke
Compared with healthy controls, samples from patients with stroke indicated that stroke induced a mild leukocytosis (median 9.3 Gpt/l; range 3.3 Gpt/l-25.6 Gpt/l; P=0.0036) dominated by neutrophils, which reached a maximum on day 1 (median 75.20%; range 46.0%-90.4%; P<0.0001). Monocytes remained unchanged, whereas the percentage of lymphocytes declined (P<0.0001), reaching its lowest value on day 1 (median 14.8%; range 2.6%-39.3%; P<0.001). Data are not shown. These findings confirm previous observations. 5,9,23,24
Migration and Phagocytosis
To evaluate the early steps in the defense of the innate immune system against bacteria after stroke, the chemotactic and phagocytic capacities of blood cells were determined. Ex vivo migration toward the chemotaxin fMLP was assessed in a standard transwell assay in granulocytes and monocytes; this migration was unaltered in patients with stroke on day 1 (data not shown). The phagocytosis of fluorescently labeled E coli by granulocytes and monocytes was quantified ex vivo. We analyzed the percentages of phagocytosing cells and the number of phagocytosed bacteria per cell as reflected by MFI. In samples from control subjects, 80% of granulocytes and 70% of monocytes phagocytosed E coli (median values); the percentage of phagocytosing cells did not significantly differ between patients with stroke and controls ( Figure 1A and 1C). The efficacy of phagocytosis (MFI) also remained unaltered in both cell types after stroke ( Figure 1B and 1D ). Taken together, these ex vivo data show that during the acute phase 
Oxidative Burst
Oxidative burst is an efficient means used by phagocytes to kill internalized bacteria. Therefore, we determined whether stroke altered the percentage or efficacy of oxidative burst in our samples. In granulocytes, spontaneous oxidative burst was observed in 3.9% of cells in the control samples. The baseline oxidative burst activity of the granulocytes of patients with stroke was significantly reduced throughout the first week compared with controls (P=0.0011). The strongest effect was seen on day 5, when spontaneous oxidative burst only occurred in 1.0% of granulocytes (Figure 2A ). This observation was paralleled by a highly significant reduction in the oxidative burst efficacy of granulocytes (P=0.0001), which persisted throughout the observation period ( Figure 2C ). fMLP acts as weak stimulant of oxidative burst; it induced burst in 7.2% of granulocytes derived from age-matched controls. In patients with stroke, the percentage of bursting granulocytes was lower at all time points, but this difference did not achieve statistical significance ( Figure 2B ). However, the efficacy of oxidative burst induced in granulocytes was strongly reduced in patients with stroke compared with controls (P=0.0001; Figure 2D ). E coli and PMA strongly stimulated oxidative burst in virtually all granulocytes of controls. Under the influence of these supramaximal stimuli, granulocytes from patients with stroke were as likely to burst as those from controls ( Figure IA and IB in the online-only Data Supplement). The efficacy of bursting was also unaltered ( Figure IC and ID in the online-only Data Supplement).
In monocytes, spontaneous oxidative burst was observed in 3.0% of the cells in control samples. After stroke, the percentage (P=0.0318) and the efficacy (P<0.0001) of spontaneously occurring oxidative burst were strongly reduced in monocytes ( Figure 3A and 3C ). This reduction was also observed after mild stimulation with fMLP ( Figure 3B and 3D ). PMA and E coli were supramaximal stimuli for peripheral blood monocytes derived from patients with stroke ( Figure IIA and IIB in the online-only Data Supplement); whereas in age-matched controls, some monocytes remained resistant to even these strong stimuli. The oxidative burst efficacy remained largely unaltered ( Figure IIC and IID in the online-only Data Supplement).
Taken together, these observations indicate an impaired oxidative burst response in granulocytes and monocytes derived from patients with stroke. This impairment was overcome by supramaximal stimulation.
Burst Related to Stroke Volume and Neurological Deficit
We assessed whether the degree of oxidative burst inhibition was related to neurological deficit or to the size of the ischemic lesion. Similar to other changes seen in SIIAs, there was no robust correlation among these parameters (data not shown).
Oxidative Burst and SAI
To determine whether early impairment of oxidative burst predisposes patients to subsequent infection, we compared granulocyte (data not shown) and monocyte ( Figure 4A-D) function of patients with and without SAI on admission. There was no significant difference observed for the percentage of bursting cells (data not shown). The oxidative burst efficacy tended to be lower in patients who developed infection; however, variability was pronounced. Remarkably, on admission, E coliinduced oxidative burst efficacy was significantly impaired in monocytes derived from patients with SAI ( Figure 4C ). Oxidative burst analysis was performed for samples from healthy control subjects (white bars) and patients with stroke (gray bars) taken on admission (d0), the next morning (d1), and on days 3, 5, and 7 (d3, d5, d7). We evaluated the percentage of bursting cells (A and B) and the efficacy mean fluorescence intensity (MFI) of oxidative burst (C and D). Unstimulated samples (A and C; n control, d0, 1, 3, 5, 7 =15, 36, 43, 39, 36, 27) and samples stimulated by N-formyl-methionyl-leucyl-phenylalanine (fMLP) ( As expected, patients with subsequent infections had more severe disease, with much larger lesions ( Table I in 
In Vitro Effects of Stress Hormones and Acetylcholine on Phagocyte Function
Stress hormones have been suggested to act as central regulators of SIIAs 6, 25, 26 ; some characteristics of SIIAs can be mimicked in cell culture by adding catecholamines. 7 Here we investigated, whether the alterations observed in patients with stroke derived phagocytes could be induced in samples from healthy individuals by in vitro exposure to the catecholamines epinephrine and norepinephrine, the glucocorticoid dexamethasone or acetylcholine. Phagocytosis remained unaltered in monocytes and granulocytes in all conditions investigated (data not shown).
In contrast, the fraction of phagocytes spontaneously generating an oxidative burst was decreased after treatment with norepinephrine ( Figures IIIA and IVA Because other cell functions remained intact, this observation is not attributable to toxicity.
HNPs 1 to 3
The serum concentrations of HNPs 1 to 3 were increased in patients with stroke but, when the data were corrected for granulocyte counts, no differences were detected (data not shown).
NETs in Stroke
After NETosis by neutrophils, pathogens are trapped within nets of condensed chromatin. We quantified the percentage (median) of NETosing cells and assessed the area (median) covered by a cell undergoing NETosis (efficacy; Figure 5A -C).
Without stimulation, 2.1% of granulocytes from samples from healthy controls released NETs with an area of 472 μm 2 , similar to granulocytes from patients with stroke on days 1 (2.0%; 504 μm -) and with stroke-associated bacterial infections (SAI+). Efficacy mean fluorescence intensity (MFI) of oxidative burst by monocytes was compared between patients without SAI (white bars) and patients with SAI (gray bars) on admission (d0) for unstimulated cells (SAI− n d0 =11; SAI+ n d0 =6) and different stimuli like N-formyl-methionyl-leucyl-phenylalanine (fMLP) (SAI− n d0 =12; SAI+ n d0 =5), Escherichia coli (SAI− n d0 =12; SAI+ n d0 =6), and phorbol 12-myristate 13-acetate (PMA; SAI− n d0 =12; SAI+ n d0 =4 
Discussion
Whether the innate immune system is impaired in patients with stroke is unknown. Therefore, we investigated monocyte and granulocyte functions involved in bacterial defense. Although migration and phagocytic functions remained intact in monocytes and granulocytes in the present investigation, the key mechanisms required for bacterial killing, oxidative burst, and NETosis were significantly impaired in patients with stroke. These findings are in good agreement with a study describing impaired burst in 17 patients with hemorrhagic stroke. 19 Stroke localization and stroke lateralization have been suggested to contribute to the extent of immunologic changes seen in patients with stroke. [27] [28] [29] This could explain our finding that oxidative burst was not correlated to stroke severity in our cohort.
The alterations in NETosis were transient and had normalized on day 5, inhibition of oxidative burst persisted throughout the study period. Because these impaired phagocyte responses were present on admission and on day 1, they could contribute to susceptibility for SAI, which typically manifest around day 3.
To explore whether the changes seen in the bactericidal functions in cells of the innate immune system correlate with SAI in our patient cohort, we compared patients who remained completely free from infection (SAI−) and those with subsequent severe systemic infection (SAI+) according to predefined criteria. There were no significant differences between patients who are SAI+ and SAI− with respect to granulocyte oxidative burst function. In monocytes, E coli-induced oxidative burst was reduced on admission in patients with SAI. This was not observed for other stimuli. It is tempting to speculate that the in vitro response to a bacterial stimulus would be most closely related to the in vivo situation.
Stress hormones and especially catecholamines have been identified because important mediators of several SIIAs and catecholamine serum concentrations have been correlated with SAI. 3, 28 We observed that in vitro exposure of granulocytes and monocytes to catecholamines did not alter phagocytosis but inhibited oxidative burst. Thus, the results of our cell-culture experiments parallel our ex vivo findings and strengthen the case for a causal role of catecholamines in SIIAs.
We are aware of the limitations of the current study: The in vitro testing of key steps of bacterial defense mechanism was performed in cells derived from the peripheral blood of healthy donors and patients with stroke. Although this approach is often used in patient studies, it does not extend to cells that have left the blood stream to accumulate at the site of infection, also it does not address the clearance of bacteria from the host. Experimental stroke models will be required to clarify the causal relationship between impairment of phagocyte functions and SAI and to determine bacterial clearance from the host.
To further delineate the relationship of phagocyte function, stroke localization and infection larger patient cohorts will have to be studied; such a study will also reveal whether our in vitro finding that stress hormones impair phagocyte function is reflected in patients with stroke.
Stroke-induced alterations in adaptive immune function, especially the strong reduction of blood lymphocyte counts, are closely associated with early bacterial infection. 5, 24 Although this correlation is robust, it is difficult to explain how the adaptive immune system affects the early defense against bacteria. Considering that catecholamines, which suppress phagocyte function in vitro and have been shown to induce lymphocytopenia, the stress hormones could be the missing link in this mechanism. Reducing oxidative burst and NET formation impairs the defense against bacteria and thus increases the risk of infection. We propose that peripheral blood lymphopenia can serve as a biomarker of such innate immune defects, which are newly recognized features of SIIA. Whether the persistent, profound lymphopenia observed in some patients with stroke affects early innate defense mechanisms merits further study.
Conclusions
We have demonstrated the impairment of bactericidal phagocyte function in patients with stroke. This impairment is a novel aspect of SIIA. We hypothesize that the suppression of bacterial killing is causally related to the enhanced infection risk of patients with stroke.
SUPPLEMENTAL MATERIAL Supplemental methods
Migration
Cell migration was assayed using the MIGRATEST Kit® (Glycotope Biotechnology GmbH, Heidelberg, Germany) according to the manufacturer's instructions. Briefly, leukocyte-rich plasma was extracted from whole blood. The bottom chamber of the test equipment was filled with either 350 μL of incubation buffer (control conditions) or incubation buffer enriched with the chemotactic peptide N-formyl-Met-Leu-Phe (fMLP; stimulated conditions, 50 nM fMLP final concentration). One hundred microliters of leukocyte-rich plasma were added into the top chamber. Cells were allowed to migrate for 30 min at 37 °C, 5% CO2, before the number of migrated cells was counted. Fluorescein isothiocyanate (FITC)-labeled antibody against Lselectin, propidium iodide for vital staining, and counting beads were added (5000 beads were counted). Propidium iodide staining was used to exclude dead cells. Since cell activation is inversely correlated with L-selectin expression #1 downregulation of L-Selectin can be used as an activiation marker. The effect of fMLP on cell activation was therefore assessed by calculating (percentage selectin-negative cellsstimulated) -percentage selectin-negative cellsunstimulated) = fMLP-induced activation. The migratory activity of the cells was determined as the ratio of cells to beads under stimulated and unstimulated conditions. Fluorescence-activated cell sorting (FACS) analysis was performed on a BD LSR II (BD Biosciences, San Jose, CA, USA).
